08.02.2022, Author: Nico Popp

Stock news: Defence Therapeutics facing collaborations — Success now also with HPV vaccination

  • Biotechnology

After years of hype, the prices of the best-known biotech shares have also fallen recently. The Canadian cancer hopeful Defence Therapeutics (ISIN: CA24463V1013) has also lost ground in recent months. Yet the Company is on a strong course. Defence Therapeutics has patented Accum™, a technology for drug conjugates, which it also uses for vaccinations. Two Phase 1 trials are scheduled to start against breast and skin cancer this year. In addition, Defence Therapeutics has another iron in the fire with a vaccine against human papillomavirus (HPV). As Defence CEO Sébastien Plouffe points out, some major industry players are already showing interest in collaborations. An update.

Time to read: 3 minutes

In addition to the planned Phase 1 trials around cancer vaccines, which are scheduled to start later this year, Defence Therapeutics also stands out for its antibody-drug conjugates (ADC). As we mentioned in our first comprehensive summary on Defence Therapeutics, "In this process, a specific drug is linked to an antibody by means of a peptide linker and thus reaches precisely where it is supposed to act. For example, into a tumor cell. Defence Therapeutics has data that Accum™ can significantly increase the efficacy of certain forms of therapy when combined with immune checkpoint inhibitors. Immune checkpoint inhibitors are targeted in oncology to block anti-inflammatory immune checkpoints to provide benefits in the setting of therapy."

CEO Sébastien Plouffe believes his company is on a very good path

Merck or Sanofi? The list of potential partners is prominent

Most recently, Defence Therapeutics issued a press release on the efficacy of its proprietary HPV vaccine, which makes significant use of Accum™ technology. The result: Compared to Merck's product (Gardasil-9), AccuVAC-PT009 elicits up to a factor of 36 increased immune response. "We are incredibly proud to once again demonstrate how ACCUM™ can be used and applied to significantly boost any protein-based vaccine. Not only can this vaccine have a tremendous impact on improving the immunogenicity of marketed Gardasil-9, but it can additionally reduce the dosing schedule (by at least 10-fold) and still elicit a comparable or stronger humoral immune response" said CEO, Plouffe.

Defence Therapeutics could already envision collaborations with other manufacturers last year. Due to the versatile Accum™ technology, which is suitable for enhancing the efficacy of vaccines and drugs, such collaborations are obvious. When asked, CEO Plouffe believes collaborations are possible around both protein-based Covid vaccines and vaccines against HPV. So far, the top dogs Glaxo-Smith-Kline, Merck and Sanofi have been active in these areas. The French company, in particular, could be a suitable partner for Defence Therapeutics, as the Canadians are researching similar products that can be applied nasally. Last September, Defence already reported the success of a nasally administered Covid-19 vaccine in animals: "With Defence's new AccuVAC-IN002 formulation, we are able to induce both systemic and mucosal IgA and IgG antibody responses. This would ensure a transmission-inhibitory effect that not only stops initial infection, but also ensures nearly 100% blockade of viral shedding", Plouffe said at the time. Although animal studies can only provide an initial indication of potential marketability for humans, Defence Therapeutics' multiple good results nevertheless show how great the potential of Accum™ is.

Accum™ offers flexible opportunities and opens doors to potential collaboration partners for Defence Therapeutics

Potential collaborations improve financing options

The long-term growth potential in both of Defence Therapeutics' businesses appears large: market researchers at Emergen Research project that the market for ADCs will grow 25.8% annually through 2028. The market for vaccines and other immune drugs against cancer is expected to be worth a whopping USD 163.1 billion by 2027. Given its patented technology and mounting evidence that Accum™ is safe and effective in many use cases, Defence Therapeutics remains a promising biotech company.

While many peers focus on only one product and are thus dependent on funders, not least of which is the risk of dilution for existing shareholders, Defence Therapeutics has multiple opportunities to generate revenue from licensing. This option can be considered an ace in the holefrom an investor's perspective. As conditions for growth companies worsen in the face of interest rate reversals and market dislocations, Defence Therapeutics has the potential to open up cash flows or initiate other fruitful collaborations in several areas at once.

Interim conclusion: Defence Therapeutics remains on track. While the market is becoming increasingly skeptical of lofty future plans in the tech sector, the biotech market continues to be in a gold-rush mood. Not only has Pfizer, BioNTech and Moderna taken advantage of the positive financing and approval conditions during the pandemic, but the insights of the past two years also benefit many smaller companies. With the encouraging results on HPV vaccination and several options for collaborations with large companies at the same time, Defence Therapeutics remains on a good course in 2022.

Conflict of interest

Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

For this reason, there is a concrete conflict of interest.

The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

Risk notice

Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.